CureVac, Sanofi Pasteur and In-Cell-Art Collaborate on a $33.1 Million Project Co-Funded by the U.S. Defense Advanced Research Projects Agency
4-year collaboration in field of prophylactic and therapeutic vaccines for infectious diseases
16-Nov-2011 -
CureVac GmbH announced the signing of several agreements with Sanofi Pasteur S.A., the vaccines division of Sanofi. Under these agreements, CureVac and Sanofi Pasteur will further develop and apply CureVac’s proprietary RNActive® technology platform to the development of vaccines against several ...
CureVac
infectious diseases
Sanofi Pasteur
+1